Randomized trial evaluates ctDNA dynamics for treatment outcomes in DLBCL, suggesting integration with imaging improves accuracy.
Key Points
This research aims to assess the clinical implications of ctDNA assessments in guiding treatment for DLBCL.
52 patients with advanced-stage DLBCL treated with R-CHOP underwent serial ctDNA analysis at baseline, interim, and end of treatment.
Prognostic significance of ctDNA dynamics was evaluated against PET/CT response.
Targeted next-generation sequencing was used to analyze ctDNA and its correlation with clinical factors.
Baseline ctDNA was detected in 98.1% of patients, showing 74.7% concordance with tumor tissue genotyping.
A ≥2-log reduction in ctDNA at interim was significantly associated with improved overall survival (p = 0.004).
Combining ctDNA dynamics with PET/CT results enhanced predictive accuracy for treatment outcomes, especially in patients with partial metabolic responses.